Chai Phua: 1st Publicly Funded Hemgenix Treatment for Hemophilia B in Canada Marks Historic Gene Therapy Milestone
Chai Phua, Associate Professor at Schulich School of Medicine and Dentistry, shared on LinkedIn:
”A historic milestone for bleeding disorders care in Canada.
Last week, the first publicly funded Canadian patient received Hemgenix for Hemophilia B at London Health Sciences Centre.
While this moment represents a major step forward in gene therapy and hemophilia B care, it also reflects decades of foundational work by leaders, clinicians, researchers, nurses, hemostasis laboratories, blood banks, patient advocates, and the broader bleeding disorders community across Canada who helped build the systems, expertise, and advocacy needed to make innovative therapies like this possible.
Most importantly, this milestone represents hope not only for one patient, but for the future of innovative therapies in rare diseases across Canada.
Thank you to everyone who helped make this possible.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026